Pay in 4 interest-free payments of $6.78 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Hung A, Maciejewski ML, Berkowitz TSZ, et al
Safety & Regulatory Status PT-141: FDA-Approved PT-141 (bremelanotide) completed the full FDA approval pathway: Two Phase III trials (RECONNECT) with 1,267 women Established safety profile over 24-week treatment periods Known drug interactions (minimal low CYP enzyme metabolism) Maximum frequency: one dose per 24 hours MT-2: Unregulated MT-2 has only completed Phase I clinical trials (safety/tolerability in small groups): No Phase II or III efficacy/safety data for tanning All available product is unregulated research chemical No standardized manufacturing or quality control Purity varies significantly between sources This regulatory gap is the single biggest difference in risk profile between these peptides
Manufactured by OstroVit, Poland
22 These diseases will manifest with acute liver disease, hypoglycemia, high creatine kinase, and cardiomyopathy, associated to hyperammonemia
Good Overall Health: Individuals should be in good overall health to undergo the procedure
kas arlar kronikleebilir
US$ 21.96
US$ 22.37
US$ 21.98
US$ 24.46
